Can Johnson & Johnson (JNJ) Trade At A Discount Despite Talc Risk?
Johnson & Johnson stock has delivered a strong 77.8% total return over the past five years, yet the latest valuation checks send a mixed message, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader scorecard is less generous.
- Over five years, Johnson & Johnson has returned 77.8%, which puts current buyers in the position of judging whether that run already reflects much of the good news.
- Progress in higher value oncology and autoimmune treatments can support expectations for future cash flows, while ongoing talc and related legal cases underline a risk that future outflows could weigh on what investors are willing to pay.
- On Simply Wall St’s broader checks, Johnson & Johnson passes only 2 of 6 valuation tests. This suggests the stock does not screen as a clear bargain even though the DCF work indicates the shares may trade about 34.0% below intrinsic value.
The issue now is whether that gap between a low overall valuation score and an intrinsic value estimate that points to a 34.0% discount offers enough compensation for the legal and execution risks around Johnson & Johnson.
Is Johnson & Johnson Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) valuation estimates what Johnson & Johnson’s potential future cash generation could be worth in today’s dollars. For Johnson & Johnson, the model starts with latest twelve month free cash flow of about $17.0b and assumes those cash flows keep growing over time, consistent with a large pipeline in oncology and autoimmune treatments.
On that basis, the 2 Stage Free Cash Flow to Equity model arrives at an estimated intrinsic value of about $390 per share. That implies the stock appears around 34.0% undervalued versus the current share price. The mixed stream of news, from ongoing talc verdicts to progress with drugs like Amivantamab, may help explain why the market price is below the value suggested by this cash flow profile.
Overall, the DCF work indicates Johnson & Johnson stock currently appears undervalued relative to its projected cash flows.
Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 34.0%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.
Where Does Johnson & Johnson Sit on Earnings?
The P/E multiple is a useful yardstick for Johnson & Johnson because earnings are still a central anchor for how investors look at a large, diversified pharmaceutical group. Johnson & Johnson currently trades on a P/E of about 29.5x, compared with a Pharmaceuticals industry average of around 14.9x and a peer group average near 27.8x. The stock therefore sits at a clear premium to the broader sector and only a modest premium to closer peers.
A more tailored yardstick, which looks at Johnson & Johnson’s size, margins, sector, and risk profile, points to a fair P/E ratio of roughly 28.4x. That is only slightly below the current 29.5x. This suggests the stock is priced close to what this framework would expect and that the legal headlines and oncology and autoimmune pipeline progress are largely reflected in the earnings multiple already.
On the P/E measure, Johnson & Johnson stock looks roughly fairly valued rather than clearly cheap or expensive.
See what the numbers say about this price — find out in our valuation breakdown.
The Johnson & Johnson Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the valuation work on Johnson & Johnson leaves off. They spell out which assumptions about future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each narrative links a specific set of catalysts and risks to an implied fair value, so you can later see which storyline appears closest to how Johnson & Johnson's situation develops.
Community views on Johnson & Johnson sit far apart, with one side focused on the breadth of the pipeline and the other on concentration and legal risk.
Bull case: roughly fairly valued
"Scaling across 28 platforms or products, each generating at least US$1b in annual revenue, with multiple brands such as DARZALEX, TREMFYA, CARVYKTI, ERLEADA and SPRAVATO already at high run rates, supports a broad base for potential future revenue and earnings growth rather than reliance on a single product..."
Read the full Bull Case to see why Johnson & Johnson could be undervalued
Bear case: roughly fairly valued
"The long term reliance on a small group of blockbuster drugs and devices, such as DARZALEX at over US$14b in annual sales and other multi billion dollar brands, increases exposure to patent expiries, biosimilar or generic competition and competing therapies..."
Read the full Bear Case to see why Johnson & Johnson could be overvalued
Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!
The Bottom Line
For Johnson & Johnson, the Discounted Cash Flow (DCF) work points to meaningful intrinsic value upside, while the P/E framework says the stock is priced about right relative to peers. That split reflects different emphases, with the intrinsic value view anchored on cash flow potential and the market multiple shaped by sentiment, growth assumptions and comparable companies. Broader valuation checks remain weak, so the DCF signal sits against a cautious scorecard rather than clear-cut value status. The central question from here is whether legal overhangs and execution risks justify the current discount or whether Johnson & Johnson ultimately closes more of that perceived gap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com